| Ident. | Authors (with country if any) | Title |
|---|
| 002A26 (2013) |
T. Matsubara ; H. Inoue ; M. Iwahashi ; A. Yamazaki ; T. Takeuchi [Japon] | THU0125 A multi-center, double-dummy, double-blind study of subcutaneous (SC) abatacept (ABA) compared with intraveneous (IV) ABA in japanese rheumatoid arthritis patients with inadequate response to methotrexate |
| 002A43 (2013) |
H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon] | THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan |
| 002B51 (2013) |
T. Takeuchi [Japon] ; Y. Tanaka ; K. Amano ; J. Kikuchi [Japon] ; E. Tanaka [Japon] ; S. Hirata ; H. Nagasawa ; H. Yasuoka [Japon] ; H. Yamanaka [Japon] | SAT0140 Effectiveness of Abatacept Against Rheumatoid Arthritis in Daily Clinical Practice - Orbit Study |
| 002B65 (2013) |
M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon] | SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan |
| 002B93 (2013) |
T. Kondo [Japon] ; K. Yoshimoto [Japon] ; K. Suzuki [Japon] ; H. Kameda [Japon] ; K. Amano ; T. Takeuchi [Japon] | SAT0078 Decreased peripheral CD3 zeta chain expression in patients with active rheumatoid arthritis can be restored by various biologic DMARDs and methotrexate |
| 002D30 (2013) |
T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. Mimori | OP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study) |
| 002E13 (2013) |
G. Burmester [Allemagne] ; T. Takeuchi [Japon] ; O. Barbarash [Russie] ; G. Ranganna [Royaume-Uni] ; D. Close [Royaume-Uni] ; A. Godwood [Royaume-Uni] ; D. Saurigny [Royaume-Uni] | FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study |
| 002E67 (2013) |
Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon] | FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy |
| 002F25 (2013) |
N. Nishina [Japon] ; J. Kikuchi [Japon] ; M. Hashizume [Japon] ; K. Yoshimoto [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon] | FRI0001 Baseline soluble interleukin-6 receptor levels predict the clinical effectiveness of tocilizumab in patients with rheumatoid arthritis |
| 003003 (2013) |
T. Shoda [Japon] ; T. Takeuchi [Japon] ; T. Kotani [Japon] ; K. Nagai [Japon] ; D. Wakura [Japon] ; K. Isoda [Japon] ; S. Yoshida [Japon] ; K. Hata [Japon] ; S. Makino [Japon] ; T. Hanafusa [Japon] | AB0776 Examination of changes in the prognosis and prognostic factors of microscopic polyangitis in japan |
| 003070 (2013) |
Y. Tanaka ; T. Abe ; T. Takeuchi ; A. Yamamoto ; N. Miyasaka [Japon] | AB0587 Safety and efficacy of abatacept(ABA) demonstrated in patients with rheumatoid arthritis(RA); 4-year data from phase III open-label, multicenter, long-term extension trial |
| 003071 (2013) |
Y. Tanaka ; T. Takeuchi [Japon] ; K. Amano ; E. Sato [Japon] ; M. Nawata ; H. Nagasawa ; D. Hoshi [Japon] ; K. Saito ; S. Fukuyo ; K. Hanami ; H. Kameda [Japon] ; T. Kurasawa ; Y. Kaneko [Japon] ; H. Yamanaka [Japon] | AB0586 104-weeks assessments of clinical and structural remission in rheumatoid arthritis patients with tocilizumab from the reaction study |
| 003111 (2013) |
K. Izumi [Japon] ; Y. Kaneko [Japon] ; H. Yasuoka [Japon] ; N. Seta [Japon] ; H. Kameda [Japon] ; M. Kuwana [Japon] ; T. Takeuchi [Japon] | AB0544 Efficacy and safety of tocilizumab in patients with rheumatoid arthritis in the presence or absence of previous treatment with biologics and concomitant treatment with methotrexate |
| 003177 (2013) |
Y. Kaneko [Japon] ; M. Kuwana [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon] | AB0347 Validation of the clinical remission criteria in rheumatoid arthritis at keio immunotherapy center |
| 003199 (2013) |
K. Izumi [Japon] ; Y. Kaneko [Japon] ; H. Yasuoka [Japon] ; N. Seta [Japon] ; H. Kameda [Japon] ; M. Kuwana [Japon] ; T. Takeuchi [Japon] | AB0319 Treatment with tocilizumab improved rheumatoid arthritis patients clinically and structurally regardless of the prior use of anti-tnf biologics in daily clinical practice |
| 003239 (2013) |
Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon] | AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort |
| 003286 (2013) |
J. Kikuchi [Japon] ; M. Shiina [Japon] ; M. Hashizume [Japon] ; M. Mihara [Japon] ; K. Yoshimoto [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon] | AB0163 Factors associated with the expansion of TH17 cells in peripheral blood of ra patients: Possible different effect between anti-IL-6 and anti-TNF therapies |
| 003296 (2013) |
M. Hashizume ; N. Nishina [Japon] ; J. Kikuchi [Japon] ; K. Yoshimoto [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon] | AB0054 A rapid and marked reduction of serum vegf via blocking il-6 signal was associated with early clinical responses to tocilizumab and infliximab in patients with rheumatoid arthritis. |
| 003F52 (2009) |
N. Nishimoto [Japon] ; N. Miyasaka [Japon] ; K. Yamamoto [Japon] ; S. Kawai [Japon] ; T. Takeuchi [Japon] ; J. Azuma [Japon] | Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study |
